Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $1.03 billion. The enterprise value is $1.64 billion.
Important Dates
The next confirmed earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 115.05 million shares outstanding. The number of shares has increased by 3.08% in one year.
| Current Share Class | 115.05M |
| Shares Outstanding | 115.05M |
| Shares Change (YoY) | +3.08% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 1.61% |
| Owned by Institutions (%) | 107.98% |
| Float | 113.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 18.93 |
| PS Ratio | 0.40 |
| Forward PS | 0.49 |
| PB Ratio | 1.03 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 55.06 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.64 |
| EV / EBITDA | 17.47 |
| EV / EBIT | 704.09 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.85, with a Debt / Equity ratio of 0.60.
| Current Ratio | 0.85 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 6.98 |
| Debt / FCF | n/a |
| Interest Coverage | 0.09 |
Financial Efficiency
Return on equity (ROE) is -5.06% and return on invested capital (ROIC) is 0.08%.
| Return on Equity (ROE) | -5.06% |
| Return on Assets (ROA) | 0.06% |
| Return on Invested Capital (ROIC) | 0.08% |
| Return on Capital Employed (ROCE) | 0.13% |
| Revenue Per Employee | $567,720 |
| Profits Per Employee | -$20,768 |
| Employee Count | 4,500 |
| Asset Turnover | 0.98 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.41M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.31% in the last 52 weeks. The beta is 1.20, so Evolent Health's price volatility has been higher than the market average.
| Beta (5Y) | 1.20 |
| 52-Week Price Change | -69.31% |
| 50-Day Moving Average | 9.56 |
| 200-Day Moving Average | 17.17 |
| Relative Strength Index (RSI) | 43.15 |
| Average Volume (20 Days) | 2,441,704 |
Short Selling Information
The latest short interest is 16.09 million, so 13.98% of the outstanding shares have been sold short.
| Short Interest | 16.09M |
| Short Previous Month | 13.90M |
| Short % of Shares Out | 13.98% |
| Short % of Float | 14.21% |
| Short Ratio (days to cover) | 7.08 |
Income Statement
In the last 12 months, Evolent Health had revenue of $2.55 billion and -$93.45 million in losses. Loss per share was -$0.81.
| Revenue | 2.55B |
| Gross Profit | 367.35M |
| Operating Income | 2.33M |
| Pretax Income | -88.91M |
| Net Income | -93.45M |
| EBITDA | 94.00M |
| EBIT | 2.33M |
| Loss Per Share | -$0.81 |
Full Income StatementBalance Sheet
The company has $104.20 million in cash and $713.67 million in debt, giving a net cash position of -$609.47 million or -$5.30 per share.
| Cash & Cash Equivalents | 104.20M |
| Total Debt | 713.67M |
| Net Cash | -609.47M |
| Net Cash Per Share | -$5.30 |
| Equity (Book Value) | 1.19B |
| Book Value Per Share | 8.70 |
| Working Capital | -108.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $18.77 million and capital expenditures -$33.12 million, giving a free cash flow of -$14.35 million.
| Operating Cash Flow | 18.77M |
| Capital Expenditures | -33.12M |
| Free Cash Flow | -14.35M |
| FCF Per Share | -$0.12 |
Full Cash Flow StatementMargins
Gross margin is 14.38%, with operating and profit margins of 0.09% and -2.41%.
| Gross Margin | 14.38% |
| Operating Margin | 0.09% |
| Pretax Margin | -2.47% |
| Profit Margin | -2.41% |
| EBITDA Margin | 3.68% |
| EBIT Margin | 0.09% |
| FCF Margin | n/a |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.08% |
| Shareholder Yield | n/a |
| Earnings Yield | -9.05% |
| FCF Yield | -1.39% |
Dividend DetailsAnalyst Forecast
The average price target for Evolent Health is $16.64, which is 85.30% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.64 |
| Price Target Difference | 85.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 8.95% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 1.8 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.8 |
| Piotroski F-Score | 5 |